TY - JOUR
T1 - Hereditary Angioedema
T2 - A Review of the Current and Evolving Treatment Landscape
AU - Betschel, Stephen D.
AU - Banerji, Aleena
AU - Busse, Paula J.
AU - Cohn, Danny M.
AU - Magerl, Markus
N1 - Funding Information: Conflicts of interest: S. D. Betschel receives advisor fees from BioCryst , CSL Berhring, Ionis, KalVista, Pharvaris, and Takeda . A. Banerji receives research grant support from Takeda , KalVista, and Ionis, and serves on advisory boards for Takeda , KalVista, Ionis, BioCryst , Pharvaris, and Biomarin. P. J. Busse receives support from CSL, BioMarin, PRIME, Takeda , Medscape, American Academy of CME, Clinical Viewpoints, KalVista, BioCryst , Regeneron , CVS, and Novartis . D. M. Cohn receives consultancy fees from BioCryst, CSL Behring, Ionis, KalVista, Pharming Technologies, Pharvaris, and Takeda. He also reports speaking fees from CSL Behring , Ionis, and Takeda . M. Magerl is/was advisor/speaker/investigator for CSL Behring, Pharming, Biocryst, Ionis, Kalvista, Octapharma, Pharvaris, Intellia, and Shire/Takeda. Publisher Copyright: © 2023 American Academy of Allergy, Asthma & Immunology
PY - 2023/8
Y1 - 2023/8
N2 - Hereditary angioedema (HAE) is a rare disease characterized by sudden and often unprovoked episodes of swelling that can be potentially life-threatening when it involves the upper airway. The treatment options for both acute episodes of HAE and LTP, used to minimize the frequency and severity of angioedema attacks, were limited historically to very few options, had considerable side effects, and/or had considerable burden of treatment. Fortunately, through the elucidation of the pathophysiology of HAE, the development of newer targeted therapies has been possible both for acute therapy and long-term prophylaxis and even more are on the horizon. Because of the rapid development of these therapies, it can be challenging for clinicians to keep abreast of newer and developing treatments for HAE. This review article will outline the current and potential future treatments for HAE. It will also highlight important considerations when treating special HAE patient populations including women and pediatric patients.
AB - Hereditary angioedema (HAE) is a rare disease characterized by sudden and often unprovoked episodes of swelling that can be potentially life-threatening when it involves the upper airway. The treatment options for both acute episodes of HAE and LTP, used to minimize the frequency and severity of angioedema attacks, were limited historically to very few options, had considerable side effects, and/or had considerable burden of treatment. Fortunately, through the elucidation of the pathophysiology of HAE, the development of newer targeted therapies has been possible both for acute therapy and long-term prophylaxis and even more are on the horizon. Because of the rapid development of these therapies, it can be challenging for clinicians to keep abreast of newer and developing treatments for HAE. This review article will outline the current and potential future treatments for HAE. It will also highlight important considerations when treating special HAE patient populations including women and pediatric patients.
KW - Hereditary angioedema
UR - http://www.scopus.com/inward/record.url?scp=85162255419&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.jaip.2023.04.017
DO - https://doi.org/10.1016/j.jaip.2023.04.017
M3 - Article
C2 - 37116793
SN - 2213-2198
VL - 11
SP - 2315
EP - 2325
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 8
ER -